DCOY · NASDAQ
Decoy Therapeutics (DCOY) Stock Price & Fundamentals
Decoy Therapeutics (DCOY) closed at $649.32 on Oct 9, 2026, up 0.12% from the previous close of $648.57.
Share price, past year
1Y +62.55%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $649.32 |
| Sep 30, 2026 | $665.77 |
| Aug 31, 2026 | $604.92 |
| Jul 31, 2026 | $567.71 |
| Jun 30, 2026 | $589.24 |
| May 29, 2026 | $542.71 |
| Apr 30, 2026 | $510.47 |
| Mar 31, 2026 | $472.33 |
| Feb 27, 2026 | $426.58 |
| Jan 30, 2026 | $434.61 |
| Dec 31, 2025 | $443.81 |
| Nov 28, 2025 | $439.04 |
| Oct 31, 2025 | $416.14 |
Key statistics
- Market cap
- $345.42M
- P/E (TTM)
- 3.5
- EPS (TTM)
- $183.54
- Revenue (TTM)
- —
- Net income (TTM)
- −$14.45M
- Shares outstanding
- 532K
- Dividend yield
- —
- 52-week range
- $399.19 – $667.06
Decoy Therapeutics's market cap is $345.42M, based on a share price of $649.32 and 532K shares outstanding as of Jun 30, 2026.
Financials
Decoy Therapeutics reported revenue of $0.00 for fiscal 2022, down 100.00% from fiscal 2021.
Decoy Therapeutics reported a net loss of $12.52M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2022ended Dec 31, 2022 | $0.00 | −100.0% | −$31.61M | — | −$1,784.71 | — |
| FY2021ended Dec 31, 2021 | $1.84M | −64.8% | −$12.77M | −693.8% | −$925.94 | −$10.20M |
| FY2020ended Dec 31, 2020 | $5.23M | +51.0% | −$7.35M | −140.5% | −$1,499.25 | −$10.31M |
| FY2019ended Dec 31, 2019 | $3.47M | +77.6% | −$6.94M | −200.2% | −$6,356.82 | −$11.58M |
| FY2018ended Dec 31, 2018 | $1.95M | +53.1% | −$1.67M | −85.6% | −$3,478.26 | $4.18M |
| FY2017ended Dec 31, 2017 | $1.27M | +26.1% | −$34.43M | −2,701.7% | −$5,967.02 | −$27.84M |
| FY2016ended Dec 31, 2016 | $1.01M | — | −$39.49M | −3,907.7% | −$7,286.36 | −$32.61M |
| FY2015ended Dec 31, 2015 | $0.00 | — | — | — | — | −$21.01M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $227.63K | −$2.37M | −$4.46 |
| Q2 FY2025ended Jun 30, 2025 | $0.00 | −$957.83K | −$81.21 |
| Q1 FY2023ended Mar 31, 2023 | $0.00 | — | — |
| Q4 FY2022ended Dec 31, 2022 | $0.00 | — | — |
| Q3 FY2022ended Sep 30, 2022 | $0.00 | — | — |
| Q2 FY2022ended Jun 30, 2022 | $0.00 | — | — |
| Q1 FY2022ended Mar 31, 2022 | $0.00 | — | — |
| Q4 FY2021ended Dec 31, 2021 | $0.00 | — | — |
Company profile
- Name
- Decoy Therapeutics Inc.
- Ticker
- DCOY
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 2450 Holcombe Blvd, Suite J-608, Houston, TX 77021
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001615219
Recent SEC filings
- Sep 23, 2026
- Sep 15, 2026
- Aug 12, 2026
- Jul 15, 2026
- Jun 29, 2026
- May 19, 2026
- May 8, 2026
- Apr 30, 2026
Frequently asked questions
What is Decoy Therapeutics's stock price?
Decoy Therapeutics (DCOY) closed at $649.32 on Oct 9, 2026, up 0.12% from the previous close of $648.57.
What is Decoy Therapeutics's market cap?
Decoy Therapeutics's market cap is $345.42M, based on a share price of $649.32 and 532K shares outstanding as of Jun 30, 2026.
How much revenue does Decoy Therapeutics make?
Decoy Therapeutics reported revenue of $0.00 for fiscal 2022, down 100.00% from fiscal 2021.
What is DCOY's P/E ratio?
Decoy Therapeutics's price-to-earnings ratio is 3.5, based on trailing twelve-month diluted EPS of $183.54.
Does Decoy Therapeutics pay a dividend?
Decoy Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Decoy Therapeutics Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures